Xeljanz / Xeljanz Xr (tofacitinib) - Risk Of Thrombosis

XELJANZ / XELJANZ XR Recall Summary Xeljanz and Xeljanz XR (tofacitinib) are being recalled across Canada due to an increased risk of blood clots (thrombosis). This medication is used to treat rheumatoid arthritis and other inflammatory conditions. The recall affects all patients in Canada who have been prescribed this drug.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2019-12-02

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/ac0f26c0-5c44-4b50-b2b8-d38aa2bfb7ac